Medtronic has gained CE mark for its Viva/Brava portfolio of cardiac resynchronization therapy with defibrillation (CRT-D) devices.
The family of CRT-Ds features a new algorithm, called AdaptivCRT, which by preserving patients’ normal heart rhythms and by continuously adapting to individual patient needs, improves heart failure patients’ response rate to CRT-D therapy.
Medtronic senior vice president and the Cardiac Rhythm Disease Management business president Pat Mackin said the Viva/Brava family of devices offers clinicians and their patients a new approach to CRT treatment, providing therapeutic benefit and individualized care for patients.
"AdaptivCRT enables us to deliver CRT differently, allowing for greater efficiency and ensuring maximum treatment response," Mackin added.
AdaptivCRT continually adjusts to the patient’s dynamic intrinsic conduction, and enables more natural contractions as it synchronizes ventricular contraction, according to Medtronic.
In addition, patients in the AdaptivCRT study with the algorithm experienced a reduction in right ventricular pacing by 44%, thus reducing unnecessary right ventricular pacing and extending the longevity of CRT-D devices.
Other features of the new CRT portfolio include ensure CRT suite with Cardiosync In-Office Optimization, SmartShock Technology and OptiVol 2.0 Fluid Status Monitoring.